Search
For optimal search results, please limit to 2 product keywords
If you are searching for information related to a product:
- For optimal results, please enter at least 2 search terms in addition to product name
- Example: [product name] [search term] [search term]
- Example: Product + clinical trials
- For an exact match, please include search terms in double quotations. For example: "Elevatum"
Ulcerative colitis (UC)
Crohn’s disease (CD)
For optimal search results, please limit to 2 product keywords
If you are searching for information related to a product:
- For optimal results, please enter at least 2 search terms in addition to product name
- Example: [product name] [search term] [search term]
- Example: Product + clinical trials
- For an exact match, please include search terms in double quotations. For example: "Elevatum"
Genentech Presentations & Posters at DDW 2026 for IBD
The list of congresses is a subset of Roche/Genentech posters and oral presentations for the product with data presented at scientific meetings at the DDW 2026 conference. To browse full Roche/Genentech congress presentations and posters: Visit Medically.
Poster
Afimkibart Normalizes Serum Protein Networks Toward Healthy Control Levels in Ulcerative Colitis: Results from the Phase 2b TUSCANY-2 Trial
Poster Hall, McCormick Place, Tuesday, May 5, 2026
2:30pm CT
Poster
Quantifying the Spatial Inter-Rater Reliability of Mucosal Lesion Annotations in Ulcerative Colitis
Poster Hall, Level 3, Hall F2 - McCormick Place, Mon, May 4, 2026
12:30pm - 1:30pm CT
Upcoming Conferences
Genentech will be present at the following upcoming conferences. Visit our medical booth for the latest information and connect with a Medical Science Liaison (MSL).
Oct 9-14, Nashville
American Congress of Gastroenterology
Oct 17-20, Barcelona
UEG Week 2026
Oct 10-24, San Diego
NASPGHAN
Dec 7-9, 2026, Orlando, FL
AIBD
Pipeline
Genentech’s pipeline for inflammatory bowel diseases includes multiple molecules currently under investigation across two indications in adult and pediatric patient populations.
These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.
*Currently recruiting participants.
†In Collaboration with Pfizer
Afimkibart Proposed Mechanism of Action
The role of TL1A in IBD
Watch the video
Afimkibart is an investigational monoclonal antibody, targeting the TL1A protein, being evaluated as a potential treatment for inflammatory and fibrotic diseases.
Afimkibart and its uses are investigational and have not been approved by regulatory authorities worldwide. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.
The Role of TL1A in IBD (Proposed Mechanism of Action)
Proposed mechanism of TL1A cytokine in inflammatory bowel disease and how the monoclonal antibody afimkibart is designed to block TL1A signaling.
TL1A Mechanism of Action in IBD and MASH
Description of the proposed mechanism of action for afimkibart, highlighting its potential to treat both IBD and MASH by inhibiting TL1A-mediated inflammatory and fibrotic pathways.
Afimkibart Mechanism of Action in MASH
Description of the pathogenesis of MASH and the potential role of TL1A in contributing to the chronic inflammation and fibrosis associated with this liver disease.
MASH: Metabolic Dysfunction-Associated Steatohepatitis
Actively Recruiting Clinical Trials
| Afimkibart (RO7790121) | |||
|---|---|---|---|
| Indication | Phase | Trial Name | |
| Crohn’s disease | Phase III | A Phase III, Multicenter, Double-Blind Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart in Patients With Moderately to Severely Active Crohn’s Disease (SIBERITE-1) | Visit trial |
| Crohn’s disease | Phase III | A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Asses the Efficacy and Safety of Induction Therapy With Afimkibart in Patients With Moderately to Severely Active Crohn’s Disease (SIBERITE-2) | Visit trial |
| Crohn's disease | Phase III | A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease (SIBERITE-PEDS) | Visit trial |
| Ulcerative colitis | Phase III | A Phase III, Multicenter, Double-Blind Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart in Patients With Moderately to Severely Active Ulcerative Colitis (AMETRINE-1) | Visit trial |
| Ulcerative colitis | Phase III | A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Asses the Efficacy and Safety of Induction Therapy With Afimkibart in Patients With Moderately to Severely Active Ulcerative Colitis (AMETRINE-2) | Visit trial |
| Ulcerative colitis | Phase III | A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart in Children Aged 2-17 Years With Moderately to Severely Active Ulcerative Colitis (AMETRINE-PEDS) | Visit trial |
| p40 x TL1A bispecific antibody (RO7837195) | |||
|---|---|---|---|
| Indication | Phase | Trial Name | |
| Ulcerative Colitis | Phase IIb | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) | Visit trial |
Interested in becoming an investigator or have trial questions?
Previous Conference Presentations for Afimkibart in IBD
Select each item to view more information and view the material.
ECCO 2026 | Poster
Functional Advantage of Afimkibart’s Preference for Trimeric TL1A in Blocking Active TL1A Signaling
Fuh, F
ECCO 2026 | Poster
Indirect Comparison of Afimkibart and Adalimumab Treatment Effects in Patients with Ulcerative Colitis Using Data from TUSCANY-2 and HIBISCUS
Xu, Q
ECCO 2026 | Poster
Afimkibart Fully Neutralizes TL1A Activity, Rendering DcR3-TL1A Blockade Biologically Inconsequential
Fuh, F
ECCO 2026 | Poster
Afimkibart downregulates Th17, myeloid, and fibrotic pathways in ulcerative colitis: serum proteomics from the phase 2b TUSCANY-2 trial
Chang, S
ECCO 2026 | Poster
Understanding the clinical trial experience of people living with Inflammatory Bowel Disease (IBD), and identifying unmet needs and key challenges that impact trial participation
Saldaña, R
ECCO 2026 | Poster
Assessing the Impact of Biopsy Artifacts on AI-Based Endoscopic Scoring for Ulcerative Colitis
Gomariz, A
ECCO 2026 | Digital oral
Quantifying Inter-Rater Reliability of Mucosal Features in Ulcerative Colitis Endoscopy
Blasco Fernandez, P
UEGW 2025 | Poster
Afimkibart (Anti-TL1A) Blocks Cellular Signaling Induced by Active TL1A
Fuh, F, Varfolomeev, E, Nguyen, A, et al.
UEGW 2025 | Poster
Baseline Characteristics Predicting afimkibart Remission/Benefit (TUSCANY-2)
Peyrin-Biroulet, L.
DDW 2025 | Presentation
Afimkibart: Evaluation of Histologic and Endoscopic Endpoints in UC
Jairath, V.
DDW 2025 | Poster
Afimkibart Shows Early/Rapid Symptomatic Remission in UC (TUSCANY-2)
Allegretti, J.
CCC 2025 | Poster
Afimkibart: Early Clinical Response/Symptom Improvement in UC (Phase 2b)
Allegretti, J.
UEGW 2024 | Presentation
Efficacy/Safety of afimkibart (Anti-TL1A) in UC: Phase 2b Results
Danese, S.
ACG 2024 | Presentation
TUSCANY-2 Phase 2b: Efficacy/Safety of afimkibart (Anti-TL1A) in Active UC
Danese, S.
AIBD 2024 | Poster
Efficacy & Quality of Life Results in UC (Phase 2b)
Yanur, A.
Publications
The list of publications is not an exhaustive list of published materials on the product. The list of references by data topics is selected per evidence-based medicine criteria.
To browse a full listing of published scientific literature: Visit PubMed
Stay updated
Follow us on Linkedin or X to receive the latest scientific updates from Genentech.
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT